Réf.
2023/CDDDE/9555
Type d'offre
Poste terrain
Type de contrat
Contrat de prestation de services
Domaines d'expertises
Politique de la santé ; Systèmes de santé ; Suivi et évaluation
Sous-thématique
Cancer ; Financement des systèmes de santé ; Gouvernance des systèmes de santé
Date limite de candidature
24/07/2023 16:53
Durée de la mission
Court terme
Contrat
Indépendant / Entrepreneur Individuel
Durée
From August to November 2023
Département Santé - DEPSAN > Pôle Initiative 5% et Pandémies
Mis en ligne le : 17/07/2023
The SUCCESS project is hiring a data collection consultant to work with other members of the team and collect data that are required for the costing study. The consultant will be responsible for the following:
Confidentiality of information and intellectual property
Cervical cancer is one of the most common preventable forms of cancer, but it is the fourth most common cancer among women globally and the leading cause of death among HIV-infected women.[1],[2],[3] An estimated 604,127 new cases of cervical cancer were diagnosed worldwide and 341,831 women died from the disease in 2020. An overwhelming majority (90%) of these cervical cancer deaths occur in low- and middle-income countries (LMICs), which often have poor health infrastructure.[4] Nearly all cases of cervical cancer (99%) are related to infection with high-risk human papillomavirus (HPV), an extremely common virus transmitted through sexual contact.[5],[6]
To address this situation, the World Health Organization (WHO) has launched a strategy to accelerate the elimination of cervical cancer worldwide. This strategy aims to ensure that, by 2030, 90% of girls are vaccinated against HPV, 90% of adult women have access to screening services with a highly effective test, and 70% of women with cancer or precancerous lesions receive the treatment they need.
WHO estimates that a total of USD 10.5 billion is required to finance cervical cancer eradication in low- and low-to-middle-income countries by 2030, where a large portion of this amount (equivalent to USD 1.8 per capita) should be frontloaded to rapidly establish and scale up services; 6.2 USD of this figure is needed for vaccination programs; 2.1 USD for facility utilization; 1.3 USD for consumables, 0.5 USD for human resources and 0.4 USD for equipment; by 2019 TogetHER for Health, reported that only one-seventh of this amount was invested in these countries[7].
In this context, the SUCCESS (Scale up cervical cancer elimination with secondary prevention strategy) project is supporting four countries (Guatemala, Burkina Faso, Côte d'Ivoire and the Philippines) to expand their screening programs with an emphasis on HPV DNA testing and ablative treatment of precancerous cervical lesions as part of their interventions, the project plans to estimate the costs of implementing cervical cancer prevention interventions over a 5-year period in each of the implementing countries and involves an exercise to estimate the costs of integrating secondary prevention (screening) and tertiary prevention (early treatment of precancerous lesions) into the continuum of care through services integrated into health facilities; this also includes a comparative analysis of costs in different potential scenarios.
This exercise will be conducted using an adapted version of the Costing Tool for Cervical Cancer Prevention and Control (C4P), developed for WHO. This tool is intended for use by LMIC program managers to plan cervical cancer control strategies and make multi-year cost projections. It uses a bottom-up, input-based approach (i.e., unit cost X quantity of good or service). The C4P-SUCCESS tool will reflect the country's screening and treatment algorithm.
These costs will include two broad categories:
[1]World Health Organization. Global strategy for accelerating the elimination of cervical cancer as a public health problem and its associated goals and targets for the period 2020-2030. Vol 2.; 2020.
[2] World Health Organization. Analysis and use of data from health facilities: guidance for HIV program managers.; 2018. https://www.who.int/healthinfo/FacilityAnalysisGuide_HIV.pdf
[3] Kelly HA, Sawadogo B, Chikandiwa A, et al. Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV/AIDS: effect of antiretroviral therapy. AIDS. 2017;31(2):273-285.
[4] UICC. GLOBOCAN 2020: New Global Cancer Data.; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[5] UICC. GLOBOCAN 2020: New Global Cancer Data; 2020. https://www.uicc.org/news/globocan-2020-new-global-cancer-data. https://www.uicc.org/news/globocan-2020-new-global-cancer-data.
[6]Castle PE, Glass AG, Rush BB, et al. Clinical detection of human papillomavirus predicts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol. 2012;30(25):3044-3050. doi:10.1200/JCO.2011.38.8389.
[7] WHO and Together for Health, 2020 (The Economist Intelligence Unit Limited 2021. UICC, Expertise France, Unitaid).
Required Qualifications:
Professional Skills:
Anticipated period of performance:
Liaising with:
Employed by:
Reporting to:
We invite qualified candidates to please submit a CV and a cover letter in English.
Expertise France est l’agence publique de conception et de mise en œuvre de projets internationaux de coopération technique. L’agence intervient autour de quatre axes prioritaires :
Dans ces domaines, Expertise France assure des missions d’ingénierie et de mise en œuvre de projets de renforcement des capacités, mobilise de l’expertise technique et joue un rôle d’ensemblier de projets faisant intervenir de l’expertise publique et des savoir-faire privés.